Dart, A. B. https://orcid.org/0000-0002-4718-9408
McGavock, J.
Sharma, A.
Chateau, D.
Schwartz, G. J.
Blydt-Hansen, T.
Funding for this research was provided by:
Canadian Diabetes Association (#OG-3-11-3354-AD)
Manitoba Health Research Council (#1475)
Article History
Received: 29 October 2018
Revised: 14 February 2019
Accepted: 26 March 2019
First Online: 2 May 2019
Compliance with ethical standards
:
: The iohexol (Omnipaque 300) was provided at no charge by GE Healthcare, Amersham Division (Princeton, NJ) for the purposes of this study following approval from Health Canada for this off-label use. The authors declare that they have no conflicts of interest.
: All procedures performed in this study were in accordance with the ethical standards of the institutional committee and with the 1964 Helsinki declaration and its later amendments or comparable ethical standards.